Ms. Wells has more than 20 years of experience in drug development, including leading clinical development operations for over a decade at preclinical and clinical stage biotech companies and overseeing work across clinical operations, clinical development, program management, biostatistics, data management, patient advocacy, and regulatory affairs. Ms. Wells has expertise in building out operational teams and quality infrastructure to support rapid clinical development programs as well as clinical trial start-up and execution and comes to the team with prior experience in the pediatric rare disease space, including spinal muscular atrophy and Duchenne muscular dystrophy. Ms. Wells led the Clinical Operations team at AveXis to successful approval of Zolgensma®, a gene therapy for the treatment of infants with spinal muscular atrophy; at Avadel Pharmaceuticals leading to successful approval of Lumryz™, a treatment for patients with narcolepsy; and at Marathon that led to successful approval of Emflaza® for Duchenne. Ms. Wells has managed multiple large global development programs including nearly every geographical region, with significant experience in US, Canada, Europe, Australia, and Japan, and has directly contributed to NDA/BLA filings for four successfully approved products. She also managed pivotal trial programs for four additional products that led to marketing approvals including the metastatic pancreatic cancer program at Abraxis Bioscience that resulted in approval for an indication expansion for Abraxane® and the invasive aspergillosis infection program at Astellas that resulted in approval of Cresemba®.